Skip to main content
ConductScienceScienceDex

Julie D Saba

NIH Rank #6968
Unclaimed recordClaim profile
  • R01 Holder
  • Early Career
  • Diverse Portfolio

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 1866596Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Pediatrics

NIH Funding · FY2024

Linked Award Amount
$1.7M
Full award amounts, FY2024
Award Records
3
Records listing this PI
Award-Linked Rank
#6,968
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Julie D Saba. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Julie D Saba as a PI. Multi-PI records show the full award amount for context.

  • 1R01HD113778-01R01
    Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosis
    University of California, San Francisco
    $693.5K
    award amount
  • 1R61HL171786-01R61
    Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signaling
    University of California, San Francisco
    $565.3K
    award amount
  • 1R21TR005157-01R21
    Proof-of-concept for the use of enzyme replacement therapy as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome
    University of California, San Francisco
    $463.2K
    award amount

Award organization

Organizations that administered FY2024 awards listing Julie D Saba as a PI.

FY2024 award administered by University of California, San Francisco (CA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    University of California, San Francisco
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #6968
  5. 2025
    $2M Cumulative Funding
  6. 2025
    R01 Grant Holder

Explore further

Find collaborators for Julie D Saba

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →